Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Capivasertib + Trastuzumab deruxtecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capivasertib||AZD5363|AZD 5363|AZD-5363||Akt Inhibitor (Pan) 21||Capivasertib (AZD5363) decreases PI3K/AKT/mTOR signaling by inhibition of AKT1, AKT2, and AKT3, potentially resulting in decreased cell proliferation (PMID: 22294718, PMID: 32532747, PMID: 32312891).|
|Trastuzumab deruxtecan||Enhertu||DS-8201|DS8201a|T-DXd|DS-8201fam-trastuzumab deruxtecan-nxki||HER2 (ERBB2) Antibody 57||Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, and in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04556773||Phase I||Fulvestrant + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Capivasertib + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Anastrozole + Trastuzumab deruxtecan||A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)||Recruiting||USA | FRA | CAN | BEL||6|